Long-term renal outcomes in patients with primary aldosteronism

被引:297
|
作者
Sechi, LA [1 ]
Novello, M [1 ]
Lapenna, R [1 ]
Baroselli, S [1 ]
Nadalini, E [1 ]
Colussi, GL [1 ]
Catena, C [1 ]
机构
[1] Univ Udine, Med Clin, Dept Expt & Clin Pathol & Med, Div Internal Med,Hypertens Unit, I-33100 Udine, Italy
来源
关键词
D O I
10.1001/jama.295.22.2638
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Experimental animal studies indicate that exposure to increased aldosterone levels might result in renal damage, but the clinical evidence supporting this role of aldosterone is preliminary. Objective To determine the long-term outcome of renal function in patients with primary aldosteronism after surgical or medical treatment. Design, Setting, and Participants Prospective study conducted at an Italian university medical center among a consecutive sample of 50 patients who were diagnosed as having primary aldosteronism between January 1994 and December 2001 and who were followed up for a mean of 6.4 years after treatment with adrenalectomy or spironolactone. Patients with primary aldosteronism were compared with 100 patients with essential hypertension, matched for severity and duration of hypertension. All patients were treated with antihypertensive drugs to reach a target blood pressure of less than 140/90 mm Hg. Main Outcome Measures Primary outcome measures were rates of change of glomerular filtration rate and albuminuria during follow-up. Detection of new-onset microalbuminuria and restoration of normal albumin excretion during follow-up were considered as secondary outcomes. Results At baseline, glomerular filtration rate and albuminuria were higher in patients with primary aldosteronism than those with essential hypertension. The mean blood pressure during the study was 136/81 mm Hg in the primary aldosteronism group and 137/81 mm Hg in the essential hypertension group. Glomerular filtration rate and albuminuria declined during the initial 6-month period in both groups, with a change that was significantly greater ( P <. 001 for both variables) in patients with primary aldosteronism. Subsequent rate of decline of glomerular filtration was comparable in the 2 groups, whereas albuminuria did not progress in the remainder of the follow-up. Restoration of normal albumin excretion from microalbuminuria was significantly more frequent in primary aldosteronism than in essential hypertension ( P=. 02). Conclusion In the majority of patients in this study, primary aldosteronism was characterized by partially reversible renal dysfunction in which elevated albuminuria is a marker of a dynamic rather than structural renal defect.
引用
收藏
页码:2638 / 2645
页数:8
相关论文
共 50 条
  • [1] Long-term renal outcomes in patients with primary aldosteronism (vol 295, pg 2638, 2006)
    不详
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (15): : 1842 - 1842
  • [2] Long-term outcome of renal function in primary aldosteronism
    Catena, C.
    Novello, M.
    Lapenna, R.
    Baroselli, S.
    Nadalini, E.
    Colussi, G. L.
    Favret, G.
    Sechi, L. A.
    [J]. JOURNAL OF HYPERTENSION, 2006, 24 : S362 - S363
  • [3] Long-term outcome of renal cysts in primary aldosteronism
    Novello, M.
    Catena, C.
    Nadalini, E.
    Colussi, G. L.
    Baroselli, S.
    Chiuch, A.
    Lapenna, R.
    Sechi, L.
    [J]. JOURNAL OF HYPERTENSION, 2007, 25 : S17 - S17
  • [4] Predictors of the Long-Term Outcomes in Patients With Secondary Hypertension Caused by Primary Aldosteronism
    Chiu, Chun-Chih
    Huang, Chin-Chou
    Leu, Hsin-Bang
    Wu, Tao-Cheng
    Huang, Po-Hsun
    Lin, Shing-Jong
    Chen, Jaw-Wen
    [J]. CIRCULATION, 2013, 128 (22)
  • [5] Long-term management of hypertensive patients with primary aldosteronism
    Wofford, MR
    King, DS
    Habeeb, GE
    Harkins, KG
    Stewart, JL
    Wyatt, SB
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 256A - 256A
  • [6] Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease
    Nakano, Yujiro
    Murakami, Masanori
    Hara, Kazunari
    Fukuda, Tatsuya
    Horino, Masato
    Takeuchi, Akira
    Niitsu, Yoshihiro
    Shiba, Kumiko
    Tsujimoto, Kazutaka
    Komiya, Chikara
    Yokoyama, Minato
    Ikeda, Kenji
    Yoshimoto, Takanobu
    Fujii, Yasuhisa
    Yamada, Tetsuya
    [J]. CLINICAL ENDOCRINOLOGY, 2023, 98 (03) : 323 - 331
  • [7] The predictors of long-term outcomes after targeted therapy for primary Aldosteronism
    Chen, Ying-Ying
    Huang, Shun-Chen
    Pan, Chien-Ting
    Peng, Kang-Yung
    Lin, Liang-Yu
    Chan, Chieh-Kai
    Shun, Chia-Tung
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2024, 123 : S135 - S140
  • [8] Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism
    Mulatero, Paolo
    Monticone, Silvia
    Bertello, Chiara
    Viola, Andrea
    Tizzani, Davide
    Iannaccone, Andrea
    Crudo, Valentina
    Burrello, Jacopo
    Milan, Alberto
    Rabbia, Franco
    Veglio, Franco
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (12): : 4826 - 4833
  • [9] Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism
    Xiaotong Wang
    Qin Luo
    Menghui Wang
    Junli Hu
    Delian Zhang
    Weiwei Zhang
    Guoliang Wang
    Nanfang Li
    [J]. Hypertension Research, 2021, 44 : 426 - 434
  • [10] Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism
    Wang, Xiaotong
    Luo, Qin
    Wang, Menghui
    Hu, Junli
    Zhang, Delian
    Zhang, Weiwei
    Wang, Guoliang
    Li, Nanfang
    [J]. HYPERTENSION RESEARCH, 2021, 44 (04) : 426 - 434